Vanessa Gauttier

USPTO Granted Patents = 7 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 17)

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Rezé, FR (2022)
Reze, FR (2024)

Company Filing History:

7 out of 28

Ose Immunotherapeutics

Institut National De La Sante Et De La Recherche Medicale

patents

4. 1 out of 38

Inserm (institut National De La Sante Et De La Recherche Medicale)

patents

where one patent can have more than one assignee

Years Active: 2022-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448454 - Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof (2025-10-21),

2. 12331115 - Uses of anti-SIRPg antibodies (2025-06-17),

3. 12252546 - Anti-SIRPa antibodies and their therapeutic applications (2025-03-18),

4. 12091464 - Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1) (2024-09-17),

5. 11884723 - Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (2024-01-30),

6. 11365257 - Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) (2022-06-21),

7. 11279766 - Anti-SIRPa antibodies and their therapeutic applications (2022-03-22),

Title: The Innovative Contributions of Vanessa Gauttier

Introduction

Vanessa Gauttier is a prominent inventor based in Rezé, France. She has made significant contributions to the field of immunotherapy, holding a total of seven patents. Her work focuses on developing innovative solutions for treating various medical conditions.

Latest Patents

Among her latest patents is the invention titled "Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof." This invention provides specific humanized anti-CLEC-1A antibodies that can bind to the CLEC-1A receptor, antagonizing its interaction with endogenous ligands. These compounds have the potential to treat deleterious conditions effectively. Another notable patent is related to the "Uses of anti-SIRPg antibodies," which outlines new applications for these antibodies in the treatment and prevention of autoimmune disorders or diseases.

Career Highlights

Throughout her career, Vanessa has worked with notable organizations such as Ose Immunotherapeutics and Université de Nantes. Her experience in these institutions has allowed her to advance her research and contribute to the development of groundbreaking therapies.

Collaborations

Vanessa has collaborated with esteemed colleagues, including Nicolas Poirier and Bernard Vanhove, to further her research and innovations in immunotherapy.

Conclusion

Vanessa Gauttier's work exemplifies the impact of innovative thinking in the medical field. Her patents and collaborations highlight her commitment to advancing immunotherapy and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.